Ultragenyx Pharmaceutical (RARE) Capital Expenditures Growth (1y) (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.71 Bn | 2.30 Bn | 106.00 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | -88.51% |
| Sep 30, 2025 | -78.48% |
| Jun 30, 2025 | 830.71% |
| Mar 31, 2025 | -21.88% |
| Dec 31, 2024 | 124.99% |
| Sep 30, 2024 | 60.70% |
| Jun 30, 2024 | -102.73% |
| Mar 31, 2024 | -94.89% |
| Dec 31, 2023 | -134.14% |
| Sep 30, 2023 | 108.66% |
| Jun 30, 2023 | -54.93% |
| Mar 31, 2023 | -22.22% |
| Dec 31, 2022 | 351.47% |
| Sep 30, 2022 | -307.55% |
| Jun 30, 2022 | 54.07% |
| Mar 31, 2022 | 96.08% |
| Dec 31, 2021 | -183.04% |
| Sep 30, 2021 | 443.92% |
| Jun 30, 2021 | 391.57% |